{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=66", "query": { "intervention": "Placebo- C", "page": 66 }, "page_size": 10 }, "pagination": { "page": 66, "page_size": 10, "total_count": 1835, "total_pages": 184, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=67&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=65&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T09:20:57.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07122986", "title": "A Study to Learn About a Vaccine Against E Coli in Healthy Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "E coli vaccine 1 Dose A", "type": "DRUG" }, { "name": "E coli vaccine 1 Dose B", "type": "DRUG" }, { "name": "E coli vaccine 2", "type": "DRUG" }, { "name": "E coli vaccine 3", "type": "DRUG" }, { "name": "E coli Vaccine 4 Dose A", "type": "DRUG" }, { "name": "E coli Vaccine 4 Dose B", "type": "DRUG" }, { "name": "E coli Vaccine 4 Dose C", "type": "DRUG" }, { "name": "E coli Vaccine 5 Dose A", "type": "DRUG" }, { "name": "E coli Vaccine 5 Dose B", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 200, "start_date": "2025-08-11", "completion_date": "2028-05-08", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 11, "location_summary": "Anaheim, California • Lake Forest, California • Walnut Creek, California + 6 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lake Forest", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07122986" }, { "nct_id": "NCT06321796", "title": "Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pitt Hopkins Syndrome" ], "interventions": [ { "name": "MTP-101P", "type": "COMBINATION_PRODUCT" }, { "name": "Vancomycin", "type": "COMBINATION_PRODUCT" }, { "name": "Magnesium Citrate", "type": "COMBINATION_PRODUCT" }, { "name": "Antacid", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo MTP-101P", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo Vancomycin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Gut-Brain-Axis Therapeutics Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "5 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2024-02-27", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06321796" }, { "nct_id": "NCT02935673", "title": "Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Viruses" ], "interventions": [ { "name": "lumicitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2016-10-25", "completion_date": "2018-07-17", "has_results": true, "last_update_posted_date": "2019-12-24", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 10, "location_summary": "Fresno, California • Orange, California • Stanford, California + 7 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Eustis", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935673" }, { "nct_id": "NCT03920228", "title": "Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pachyonychia Congenita" ], "interventions": [ { "name": "PTX-022", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palvella Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2019-04-01", "completion_date": "2020-10-19", "has_results": false, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03920228" }, { "nct_id": "NCT00295633", "title": "A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" }, { "name": "rosiglitazone", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "77 Years", "sex": "ALL", "summary": "18 Years to 77 Years" }, "enrollment_count": 565, "start_date": "2006-03", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2015-04-07", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 79, "location_summary": "Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more", "locations": [ { "city": "Haleyville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295633" }, { "nct_id": "NCT02455011", "title": "Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus", "Diabetes" ], "interventions": [ { "name": "REMD-477", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "REMD Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2015-09", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-04-10", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 3, "location_summary": "Miami, Florida • San Antonio, Texas • Renton, Washington", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455011" }, { "nct_id": "NCT00859716", "title": "ACE393-103 Vaccination Challenge Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Campylobacter Infection" ], "interventions": [ { "name": "ACE393", "type": "BIOLOGICAL" }, { "name": "Placebo vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TD Vaccines A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2008-10", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2009-03-11", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859716" }, { "nct_id": "NCT00096863", "title": "The MIND Study: Modifying the INcidence of Delirium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Delirium", "Cognition Disorders" ], "interventions": [ { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2004-12", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 5, "location_summary": "Iowa City, Iowa • Chapel Hill, North Carolina • Greensboro, North Carolina + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096863" }, { "nct_id": "NCT00439244", "title": "Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoporosis" ], "interventions": [ { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Teriparatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "45 Years to 89 Years · Female only" }, "enrollment_count": 412, "start_date": "2006-12", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2011-04-20", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439244" }, { "nct_id": "NCT06790771", "title": "Effect of Supplement on Appetite and GLP-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hunger" ], "interventions": [ { "name": "High Dose Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Low Dose Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Texas Christian University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2025-01-15", "completion_date": "2026-03-15", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-04T09:20:57.375Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06790771" } ] }